Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy

The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hue, Hyejeong, Kim, Kidong, Kim, HyoJin, Suh, Dong Hoon, No, Jae Hong, Kim, Yong Beom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629981/
https://www.ncbi.nlm.nih.gov/pubmed/31338347
http://dx.doi.org/10.5468/ogs.2019.62.4.285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629981/
https://www.ncbi.nlm.nih.gov/pubmed/31338347
http://dx.doi.org/10.5468/ogs.2019.62.4.285

Ejemplares similares